Survey finds strong veterinary support for stem cell therapy: full analysis

Veterinary professionals appear increasingly aligned around the idea that stem cell therapy could move from niche to mainstream for inflammatory disease management. In a newly released AAHA-Gallant survey, 95% of respondents said stem cell therapy is likely to become a standard treatment option within 10 years, and nearly 93% said they’d be more likely to use regenerative therapy if it were offered as a ready-to-use, off-the-shelf IV product. (gallant.com)

That optimism reflects a long-running frustration in companion animal medicine: many chronic inflammatory conditions remain difficult to control, and available therapies often focus on symptom suppression rather than disease modification. In the survey, roughly 87% of respondents agreed current treatments primarily manage symptoms, not root causes. The respondent pool was weighted toward companion animal practice, with veterinarians making up 70.4% of participants and veterinary technicians 29.6%. (gallant.com)

The survey also lands at a moment when regenerative medicine is moving closer to formal regulatory review in veterinary care. Gallant, which partnered with AAHA on the survey, has been advancing an allogeneic, ready-to-use mesenchymal stromal cell therapy for refractory feline chronic gingivostomatitis. According to dvm360’s reporting on the company’s September 2025 announcement, FDA’s Center for Veterinary Medicine issued a complete letter for the reasonable expectation of effectiveness technical section, a step Gallant said supported its push toward conditional approval. Gallant had said at that time it was targeting early 2026 for conditional approval. (dvm360.com)

Gallant has also published clinical field-study details that help explain why inflammatory disease is a focal point. In its 90-day prospective study in 46 client-owned cats with refractory FCGS, conducted across nine US veterinary dental specialty centers, the company reported no treatment-related serious adverse events. By Day 90, 79% of evaluable cats met the threshold for treatment success based on owner-reported quality-of-life outcomes, 76% were rated improved by their pet parents, and 45% showed measurable oral-lesion improvement. The study was published in the Journal of Feline Medicine and Surgery, according to Gallant’s summary. (gallant.com)

Outside the company’s own materials, the broader literature supports why clinicians are paying attention, while also underscoring that the field is still developing. A 2024 review of feline MSC research found there were still no approved stem cell products available for use in cats in the US at that time. Meanwhile, published research continues to explore inflammatory applications ranging from feline inflammatory bowel disease models to dermatologic and oral inflammatory disease, reinforcing the biologic rationale for MSCs’ immunomodulatory role without yet settling all questions around durability, indication selection, and standardization. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, the real signal here isn’t just enthusiasm. It’s that clinician demand, product development, and regulatory structure may finally be starting to line up. If off-the-shelf MSC therapies reach the market through FDA review, that could begin to shift regenerative medicine away from bespoke or lightly standardized use and toward labeled, clinic-ready products with clearer manufacturing controls and prescribing boundaries. FDA notes that conditional approval requires safety and a reasonable expectation of effectiveness, but does not permit extra-label use, which would be an important operational constraint for practices considering adoption. (fda.gov)

There’s also a practical takeaway in the survey’s strongest implementation finding: convenience matters. The high percentage of respondents who said they’d be more likely to use a simple IV, ready-to-use product suggests that workflow and accessibility may be as important as scientific promise in determining uptake. For busy small-animal practices, that could shape which regenerative platforms gain traction first. (gallant.com)

What to watch: The next milestone is whether Gallant, or any other developer, actually secures FDA conditional approval in 2026 and whether early launch data support real-world use beyond initial high-need indications like refractory FCGS; if that happens, veterinary sentiment captured in this survey may start to convert into prescribing behavior. (dvm360.com)